RAPT Therapeutics Statistics
Total Valuation
RAPT has a market cap or net worth of $146.53 million. The enterprise value is -$80.04 million.
Important Dates
The next estimated earnings date is Thursday, May 8, 2025, before market open.
| Earnings Date | May 8, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
RAPT has 132.01 million shares outstanding. The number of shares has increased by 6.32% in one year.
| Current Share Class | 132.01M |
| Shares Outstanding | 132.01M |
| Shares Change (YoY) | +6.32% |
| Shares Change (QoQ) | +20.01% |
| Owned by Insiders (%) | 0.51% |
| Owned by Institutions (%) | 34.61% |
| Float | 58.45M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.77 |
| P/TBV Ratio | 0.77 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.87, with a Debt / Equity ratio of 0.02.
| Current Ratio | 4.87 |
| Quick Ratio | 4.78 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -77.09% and return on invested capital (ROIC) is -48.84%.
| Return on Equity (ROE) | -77.09% |
| Return on Assets (ROA) | -41.13% |
| Return on Invested Capital (ROIC) | -48.84% |
| Return on Capital Employed (ROCE) | -70.90% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.91M |
| Employee Count | 68 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -86.48% in the last 52 weeks. The beta is -0.29, so RAPT's price volatility has been lower than the market average.
| Beta (5Y) | -0.29 |
| 52-Week Price Change | -86.48% |
| 50-Day Moving Average | 1.19 |
| 200-Day Moving Average | 1.84 |
| Relative Strength Index (RSI) | 42.59 |
| Average Volume (20 Days) | 1,001,088 |
Short Selling Information
The latest short interest is 2.67 million, so 2.02% of the outstanding shares have been sold short.
| Short Interest | 2.67M |
| Short Previous Month | 2.63M |
| Short % of Shares Out | 2.02% |
| Short % of Float | 4.57% |
| Short Ratio (days to cover) | 5.84 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -136.10M |
| Pretax Income | -120.43M |
| Net Income | -129.87M |
| EBITDA | -134.90M |
| EBIT | -136.10M |
| Earnings Per Share (EPS) | -$3.19 |
Full Income StatementBalance Sheet
The company has $231.06 million in cash and $4.49 million in debt, giving a net cash position of $226.56 million or $1.72 per share.
| Cash & Cash Equivalents | 231.06M |
| Total Debt | 4.49M |
| Net Cash | 226.56M |
| Net Cash Per Share | $1.72 |
| Equity (Book Value) | 189.90M |
| Book Value Per Share | 1.44 |
| Working Capital | 186.89M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$83.30 million and capital expenditures -$122,000, giving a free cash flow of -$83.42 million.
| Operating Cash Flow | -83.30M |
| Capital Expenditures | -122,000 |
| Free Cash Flow | -83.42M |
| FCF Per Share | -$0.63 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |